Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Precision Biosciences (DTIL) over the last 6 years, with Q3 2025 value amounting to $66.9 million.

  • Precision Biosciences' Total Non-Current Liabilities fell 1402.34% to $66.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.9 million, marking a year-over-year decrease of 1402.34%. This contributed to the annual value of $70.0 million for FY2024, which is 4653.61% down from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' Total Non-Current Liabilities is $66.9 million, which was down 1402.34% from $64.9 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Total Non-Current Liabilities ranged from a high of $203.1 million in Q1 2021 and a low of $64.9 million during Q2 2025
  • Over the past 5 years, Precision Biosciences' median Total Non-Current Liabilities value was $119.6 million (recorded in 2021), while the average stood at $119.7 million.
  • Over the last 5 years, Precision Biosciences' Total Non-Current Liabilities had its largest YoY gain of 5401.34% in 2022, and its largest YoY loss of 4993.06% in 2022.
  • Quarter analysis of 5 years shows Precision Biosciences' Total Non-Current Liabilities stood at $110.3 million in 2021, then soared by 52.03% to $167.7 million in 2022, then dropped by 21.95% to $130.9 million in 2023, then crashed by 46.54% to $70.0 million in 2024, then decreased by 4.46% to $66.9 million in 2025.
  • Its Total Non-Current Liabilities stands at $66.9 million for Q3 2025, versus $64.9 million for Q2 2025 and $65.1 million for Q1 2025.